Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00878904|
Recruitment Status : Completed
First Posted : April 9, 2009
Last Update Posted : March 24, 2017
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with epirubicin may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with epirubicin in treating patients with metastatic malignant solid tumors.
|Condition or disease||Intervention/treatment||Phase|
|Unspecified Adult Solid Tumor, Protocol Specific||Drug: epirubicin hydrochloride Drug: panobinostat Genetic: gene expression analysis Genetic: protein expression analysis Genetic: western blotting Other: immunologic technique Other: laboratory biomarker analysis Other: pharmacological study||Phase 1|
- To determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose of panobinostat when administered with epirubicin hydrochloride in patients with metastatic malignant solid tumors.
- To determine the correlation between the pharmacokinetic profile of panobinostat drug levels and the pharmacodynamic effect of panobinostat on histone acetylation in peripheral blood mononuclear cells (PBMCs).
- To determine the effect of panobinostat on histone acetylation and chromatin remodeling proteins (HP-1, DNMT-1, SMC1-5, Topo II).
- To determine the relevance of HDAC1, HDAC2, HDAC3, and HDAC6 expression in PBMCs as a pharmacological marker and in biopsied tumors as a predictive marker for response in patients treated at the MTD.
- To document any objective response in these patients.
OUTLINE: This is a dose-escalation study of panobinostat.
Patients receive oral panobinostat on days 1, 3, and 5 and epirubicin hydrochloride IV on day 5. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood sample collection at baseline and periodically during course 1 for panobinostat pharmacokinetic studies. Patients enrolled in the dose expansion cohort also undergo collection of tumor tissue samples by fine needle aspiration at baseline and on day 5 of course 1 (after panobinostat infusion). Blood and tissue samples are analyzed for histone acetylation, chromatin remodeling genes and proteins (HP-1, DNMT-1, SMC1-5, Topo II), and HDAC enzyme expression by immunofluorescence and western blotting.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies|
|Actual Study Start Date :||September 13, 2009|
|Primary Completion Date :||May 2013|
|Study Completion Date :||October 10, 2016|
|Experimental: treatment with Panobinostat and Epirubicin||Drug: epirubicin hydrochloride Drug: panobinostat Genetic: gene expression analysis Genetic: protein expression analysis Genetic: western blotting Other: immunologic technique Other: laboratory biomarker analysis Other: pharmacological study|
- Response as assessed by RECIST criteria [ Time Frame: 30 post end of study drug estimated to be ~24 weeks ]
- Progression as assessed by RECIST criteria [ Time Frame: 30 post end of study drug estimated to be ~24 weeks ]
- Adverse events and other symptoms as assessed by NCI CTCAE v3.0 [ Time Frame: 30 post end of study drug estimated to be ~24 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00878904
|United States, California|
|UCSF Helen Diller Family Comprehensive Cancer Center|
|San Francisco, California, United States, 94143-1711|
|Principal Investigator:||Pamela N. Munster, MD||University of California, San Francisco|